HGF and neoplasm: To address this, dedicated single- and repeated-dose PK/PD studies were executed in the HGF/MET autocrine KP-4 model, which showed comparably lower tepotinib sensitivity (moderate tumor shrinkage), meaning that higher tepotinib doses were required to achieve maximal response than in very sensitive tumors with oncogenic alterations (43).